Skip to main content

Table 3 FRAX597 combined with gemcitabine increases survival in a mouse orthotopic pancreatic cancer model

From: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Treatment

Rates ratio

95 % CI

P value

Control

7.0

1.8 ± 27.0

0.005

Gemcitabine

2.7

1.0 ± 8.7

0.09

Gemcitabine + FRAX

1.0 (ref)

  
  1. The overall statistics for the stratified Cox regression analysis were: χ 2 (2) = 9.9, p = 0.007